The majority of NKG2C⁺ NK cells express FcεR1γ and CD57 in recipients of TCD HCT with CMV reactivation. (A) FcεR1γ vs NKG2C dot plots gated on total NK cells of day 30 and day 200 after HCT from a representative recipient of TCD HCT with CMV reactivation (left). (A) Percentages of NKG2C and FcεR1γ subsets of total NK cells (right) and (B) percentages of CD57 vs FcεR1γ subsets gated on NKG2C⁺ NK cells lacking NKG2A from recipients of TCD HCT with CMV reactivation (n = 50). (C) Percentages of NKG2C⁺FcεR1γ⁺ (left) and NKG2C⁺FcεR1γ⁻ (right) NK cells after HCT of patients receiving TCD (n = 50), T-replete (n = 47), or DUCB (n = 25) allograft infusions. All patients shown experienced CMV reactivation. (D) The mean fluorescence intensity (MFI) of CD16 on NKG2C⁺FcεR1γ⁺ and NKG2C⁺FcεR1γ⁻ NK cells are depicted. Data gathered at late time points are shown. Interquartile range is depicted by a box with the middle line plotted as the median, and Tukey values are represented by whiskers and outliers. One-way ANOVA with multiple comparisons test (A-C) and paired/nonparametric t test (D) were used for statistical analysis, with ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001; ∗∗∗∗P ≤ .0001.